Guardant360® Related Clinical Outcomes in Patients Who Share Medical Records-Breast Cancer

Guardant Health, Inc.109 enrolled

Overview

The purpose of this study is to observe the routine clinical care of patients who have been diagnosed with breast cancer and have undergone Guardant360 testing.

Patients who have been diagnosed with breast cancer and have undergone Guardant360 testing will be approached regarding participation in the study. After being informed about the study and potential risks, all patients providing informed consent and access to their medical records, will provide a list of their health care providers related to their cancer treatment. Data related to their routine clinical care will be abstracted from medical records.

Study Type

OBSERVATIONAL

Enrollment

109

Conditions

Advanced Breast Cancer

Interventions

Guardant360 testDIAGNOSTIC_TEST

tumor cfDNA testing

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adults (18 years of age and older) with a diagnosis of breast cancer 2. Guardant360 test results released to the patient's physician no less than 14 days prior to initial patient contact 3. Patient has previously provided contact information (either email or phone) to Guardant Health 4. Able and willing to complete the electronic informed consent process 5. Must have access to a computer terminal or personal computing device 6. Willingness to consent to the release of medical records Exclusion Criteria: 1\. Unable to understand English

Locations (1)

Guardant Health

Redwood City, California, United States

Outcomes

Primary Outcomes

Overall Survival

The Primary Outcome measure is a composite endpoint of: overall survival, progression events, and subjects lost-to-follow-up Overall Survival is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.